MNKD · Company research
Mannkind Corporation (MNKD): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| MannKind Corporation (MNKD) Stock Price, News, Quote & History - Yahoo! Finance Canada | MannKind Corporation (MNKD) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation? - Yahoo Finance | Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 16, 2026 | neutral | 0 | 0.6 |
| MannKind to Participate in the Chardan Healthcare Conference | MannKind Corporation announced that CEO Michael Castagna will participate in a panel discussion on innovation in chronic respiratory diseases at the Chardan Healthcare Conference on October 20, 2026. The company will also conduct one-on-one investor meetings. MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, with treatments addressing diabetes, pulmonary hypertension, and fluid overload conditions. | View source ↗ | GlobeNewswire Inc. | Oct 14, 2026 | bullish | 1 | 1 |
| MNKD Stock Rises Premarket As FDA Verdict Nears – Retail Optimism Builds - Stocktwits | MNKD Stock Rises Premarket As FDA Verdict Nears – Retail Optimism Builds Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein. - Stock Titan | A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein. Stock Titan | View source ↗ | Stock Titan | Oct 10, 2026 | neutral | 0 | 0.6 |
| MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) | MannKind Corporation announced new clinical data for Furoscix ReadyFlow, an autoinjector delivering IV-equivalent diuretic therapy for heart failure and chronic kidney disease. Presented at the HFSA 2026 Annual Scientific Meeting, the data demonstrates comparable urine output to IV furosemide, consistent bioavailability across injection sites, and seamless transition capabilities from the previous On-body Infusor formulation. The product received FDA approval in July 2026 and is designed to enable earlier outpatient intervention for fluid overload management. | View source ↗ | GlobeNewswire Inc. | Oct 10, 2026 | bullish | 1 | 1 |
| MNKD Stock Price, Quote & Chart - ChartMill | MNKD Stock Price, Quote & Chart ChartMill | View source ↗ | ChartMill | Oct 2, 2026 | neutral | 0 | 0.6 |
| MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal - StocksToTrade | MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal StocksToTrade | View source ↗ | StocksToTrade | Sep 30, 2026 | neutral | 0 | 0.6 |
| MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - Timothy Sykes | MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal Timothy Sykes | View source ↗ | Timothy Sykes | Sep 30, 2026 | neutral | 0 | 0.6 |
| Steven Binder sells $128,477 of MannKind (MNKD) stock - Investing.com | Steven Binder sells $128,477 of MannKind (MNKD) stock Investing.com | View source ↗ | Investing.com | Sep 28, 2026 | neutral | 0 | 0.6 |
| Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. - Stock Titan | Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. Stock Titan | View source ↗ | Stock Titan | Sep 25, 2026 | neutral | 0 | 0.6 |
| MannKind (MNKD) Stock May Be 15% Undervalued After Inhaled GLP 1 Deal - Simply Wall Street | MannKind (MNKD) Stock May Be 15% Undervalued After Inhaled GLP 1 Deal Simply Wall Street | View source ↗ | Simply Wall Street | Sep 12, 2026 | neutral | 0 | 0.6 |
| MannKind (MNKD) Stock Faces Margin Strain Despite Stronger Product Sales - Simply Wall Street | MannKind (MNKD) Stock Faces Margin Strain Despite Stronger Product Sales Simply Wall Street | View source ↗ | Simply Wall Street | Aug 7, 2026 | neutral | 0 | 0.6 |
| Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics - Yahoo Finance | Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics Yahoo Finance | View source ↗ | Yahoo Finance | Aug 5, 2026 | neutral | 0 | 0.6 |
| MannKind (MNKD) Stock Looks Undervalued On Cash Flow Yet Mixed On Broader Checks - Yahoo Finance | MannKind (MNKD) Stock Looks Undervalued On Cash Flow Yet Mixed On Broader Checks Yahoo Finance | View source ↗ | Yahoo Finance | Jul 25, 2026 | neutral | 0 | 0.6 |
| MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Stocktwits | MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost Stocktwits | View source ↗ | Stocktwits | Jul 24, 2026 | neutral | 0 | 0.6 |
| MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data - Yahoo Finance | MannKind (MNKD) Stock And Valuation After New Afrezza And FUROSCIX Clinical Data Yahoo Finance | View source ↗ | Yahoo Finance | Jun 11, 2026 | neutral | 0 | 0.6 |
| Stocks Facing FDA Decision In May—MannKind (MNKD) - Forbes | Stocks Facing FDA Decision In May—MannKind (MNKD) Forbes | View source ↗ | Forbes | May 5, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.